Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials.,Diabetes Research and Clinical Practice

当前位置： X-MOL 学术 › Diabetes Res. Clin. Pract. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials.
Diabetes Research and Clinical Practice ( IF 6.1 ) Pub Date : 2020-02-19 , DOI: 10.1016/j.diabres.2020.108087
Besmir Nreu ₁ , Ilaria Dicembrini ₁ , Federico Tinti ₁ , Edoardo Mannucci ₁ , Matteo Monami ₁

Affiliation

Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) has been associated with cholelithiasis in a previous meta-analysis. The publication of new trials suggests the need for an update. We collected trials with GLP1-RA vs. other therapies, calculating Mantel-Haenszel odds ratio (MH-OR, 95%CI). GLP1-RA significantly increased the risk of cholelithiasis (MH-OR 1.28 [1.11, 1.48]).

中文翻译：

胰高血糖素样肽1受体治疗的患者的胆石症：随机对照试验的最新meta分析。

在先前的荟萃分析中，胰高血糖素样肽1受体激动剂（GLP1-RA）与胆石症相关。新试验的发布表明需要进行更新。我们收集了GLP1-RA与其他疗法的试验，计算出Mantel-Haenszel比值比（MH-OR，95％CI）。GLP1-RA显着增加了胆石症的风险（MH-OR 1.28 [1.11，1.48]）。

更新日期：2020-02-20

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11